Search results for "prostate"

showing 10 items of 621 documents

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study

2003

OBJECTIVE To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2–4N0–3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an objective…

medicine.medical_specialtyPerformance statusmedicine.drug_classbusiness.industryUrologyUrologyAntiandrogenmedicine.diseaseSurgeryFlutamideProstate-specific antigenchemistry.chemical_compoundProstate cancerchemistrymedicineCarcinomaHormonal therapymedicine.symptomBone painbusinessBJU International
researchProduct

Multiple Cutaneous Metastases in the Chest from Prostatic Carcinoma

2013

We report a case of multiple cutaneous metastases from prostate cancer. A 78-year-old man with an 8-year history of prostate cancer had multiple nodular lesions in the chest. Histologically, the lesion showed an abortive glandular lumina and tall columnar cells with abundant cytoplasm. Immunohistochemical staining for AE1:AE3 cytokeratin cocktail, prostate-specific antigen, and prostate-specific acid phosphatase was positive in tumor cells, confirming the diagnosis of cutaneous metastases from prostate cancer. We report this case because of the rarity of cutaneous metastases from prostatic adenocarcinoma in the chest region.

PCA3Pathologymedicine.medical_specialtyCutaneous metastases · Prostatic carcinoma · AE1:AE3 cytokeratin · Prostate-specific antigen · Prostate-specific acid phosphataseDermatologyPublished online: May 2013Prostatic carcinomaLesionProstate cancerCytokeratinAntigenlcsh:DermatologySettore MED/35 - Malattie Cutanee E VenereeCarcinomaMedicineAE1:AE3 cytokeratinProstate-specific acid phosphatasebusiness.industrylcsh:RL1-803Cutaneous metastasesmedicine.diseaseProstate-specific antigenProstate-specific antigenImmunohistochemistrymedicine.symptombusinessCase Reports in Dermatology
researchProduct

Rhabdomyosarcoma of the bladder, prostate or vagina: the role of surgery

2003

Rhabdomyosarcoma of pelvic organs is not common enough for many people to develop large series. However, the authors from Mainz retrospectively analysed 107 children with this condition, and suggest that primary chemotherapy followed by radical surgery yields excellent cure rates. OBJECTIVE To retrospectively analyse the outcome of children with rhabdomyosarcoma (RMS) of the bladder, prostate or vagina who were treated with chemotherapy, with or without radical surgery or additional radiotherapy, at our institution since 1968. PATIENTS AND METHODS From a total of 107 children with RMS seen between 1968 and December 2001, 22 (mean age 5.9, range 0.5–18) had RMS of bladder/prostate or vagina.…

Malemedicine.medical_specialtyVaginal NeoplasmsAdolescentUrologymedicine.medical_treatmentUrologyUrinary DiversionCystectomyAntineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomamedicineHumansRadical surgeryChildRhabdomyosarcomaRetrospective StudiesProstatectomyIfosfamideUrinary bladderbusiness.industryUrinary diversionInfantProstatic Neoplasmsmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureUrinary Bladder NeoplasmsBladder augmentationChild PreschoolFemalePouchbusinessContinent Urinary DiversionFollow-Up Studiesmedicine.drugBJU International
researchProduct

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma

2016

Background: NF-κB signalling appears deregulated in breast tumours. The purpose of this study was to determine whether the non-canonical NF-κB pathway, is activated in oestrogen receptor positive (ER+) breast cancer, to identify any correlation between its activity and the clinico-pathological phenotype and to explore whether NF-κB2 and RelB subunits and/or any of their target genes might be used as a predictive marker. Methods: Two independent cohorts of ER+ early breast cancer patients treated with adjuvant endocrine therapy were included in the study. Activation of RelB and NF-κB2 subunits was determined in a training set of 121 patients by measuring DNA-binding activities in nuclear ext…

0301 basic medicineOncologyAdultCancer Researchmedicine.medical_specialtyBreast NeoplasmsER-positiveNF-κBCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerbreast cancernon-canonicalInternal medicinemedicineHumansMolecular DiagnosticsAgedAged 80 and overPredictive markerOncogenebusiness.industryRELBNF-kappa BMiddle Agedmedicine.diseasePrognosis030104 developmental biologyOncologyReceptors Estrogen030220 oncology & carcinogenesisFemaleLiver cancerBreast carcinomabusinessEstrogen receptor alphaBritish Journal of Cancer
researchProduct

Inhibition of Platelet Aggregation Caused by Estrogen Treatment in Patients with Carcinoma of the Prostate

1975

Platelet aggregation is increased in patients with carcinoma of the prostate treated with estrogens. Hence, these patients have a high incidence of cardiovascular and thromboembolic diseases. Platelet aggregation has been tested with the platelet aggregation test. It was inhibited by administration of 500 mg. acetylsalicylic acid twice daily. An aggregation inhibiting effect has been found in all 38 patients. To reduce the excess hazards of cardiovascular complications of estrogens in treating carcinoma of the prostate acetylsalicylic acid is recommended as an adjunct therapy.Estrogen therapy for prostatic carcinoma may lead to the development of cardiovascular complications, such as thromb…

Malemedicine.medical_specialtyPlatelet Aggregationmedicine.drug_classUrologyPopulationPharmacologyPlatelet AdhesivenessProstateInternal medicineCarcinomaHumansEndocrine systemMedicineCastrationeducationDiethylstilbestroleducation.field_of_studyAspirinEstradiolbusiness.industryGenitourinary systemProstatic NeoplasmsCancerEstrogensmedicine.diseaseEndocrinologymedicine.anatomical_structureEstrogenbusinessHormoneJournal of Urology
researchProduct

Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases

2021

Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is 177Lu-DOTA-zoledronic acid (177Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of 177Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. Methods: Nine patients with exclusive bone metastases from metastatic castration-resistant prostate cancer (mCRPC) (70.8 ± 8.4 y) and progression under conventional therapies participated in this prospective study. After receiving 5,780 ± 329 MBq 177Lu-DOTA-ZOL, patients underwent 3-dimensional …

0301 basic medicinebusiness.industrymedicine.medical_treatmentBone metastasisBisphosphonatemedicine.disease03 medical and health sciencesProstate cancer030104 developmental biology0302 clinical medicineTherapeutic index030220 oncology & carcinogenesisRadionuclide therapymedicineDosimetryRadiology Nuclear Medicine and imagingNuclear medicinebusinessProspective cohort studyBlood drawingJournal of Nuclear Medicine
researchProduct

Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies

2020

Multiple studies have suggested that ω-3 fatty acid intake may have a protective effect on cancer risk; however, its true association with cancer risk remains controversial. We performed an umbrella review of meta-analyses to summarize and evaluate the evidence for the association between ω-3 fatty acid intake and cancer outcomes. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews from inception to December 1, 2018. We included meta-analyses of observational studies that examined associations between intake of fish or ω-3 fatty acid and cancer risk (gastrointestinal, liver, breast, gynecologic, prostate, brain, lung, and skin) and determined the level of evidence of…

MaleRiskOncologymedicine.medical_specialty[SDV]Life Sciences [q-bio]BFMedicine (miscellaneous)ReviewCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerω-3 fatty acidMeta-Analysis as TopicNeoplasmsInternal medicineFatty Acids Omega-3medicineAnimalsHumanscancer030212 general & internal medicineω-3 fatty acid fish cancer umbrella review meta-analysischemistry.chemical_classificationfishNutrition and Dieteticsumbrella reviewbusiness.industryEndometrial cancerFishesFatty acidCancermedicine.diseaseR13. Good healthmeta-analysisObservational Studies as TopicchemistryCase-Control Studies030220 oncology & carcinogenesisMeta-analysisFemaleSkin cancerbusinessLiver cancerFood Science
researchProduct

Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study

2013

Background: Cancer survival is a key measure of the effectiveness of health-care systems. EUROCARE-the largest cooperative study of population-based cancer survival in Europe-has shown persistent differences between countries for cancer survival, although in general, cancer survival is improving. Major changes in cancer diagnosis, treatment, and rehabilitation occurred in the early 2000s. EUROCARE-5 assesses their effect on cancer survival in 29 European countries. Methods: In this retrospective observational study, we analysed data from 107 cancer registries for more than 10 million patients with cancer diagnosed up to 2007 and followed up to 2008. Uniform quality control procedures were a…

GerontologyAdultMaleTime FactorsAdolescentColorectal cancerPopulationSettore MED/42 - Igiene Generale E ApplicataIR-88481NOProstate cancerBreast cancerMETIS-300341NeoplasmsmedicineHumansLung cancereducationAdolescent; Adult; Age Factors; Aged; Europe; Female; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Time Factorsddc:613AgedRetrospective Studieseducation.field_of_studyRelative survivalbusiness.industryOncology cancer survival eurocareAge FactorsCancerRetrospective cohort studycancer survival ; age ; country ; Europe ; Eurocare 5Middle Agedmedicine.diseaseCancer survivalEuropeOncologyFemaleNeoplasms/mortalitybusinessDemography
researchProduct

[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile a…

2010

[11C]choline positron emission tomograhy can be useful to detect metastatic disease and to localize isolated lymph node relapse after primary treatment in case of prostate-specific antigen failure. In case of lymph node failure in prostate cancer patients, surgery or radiotherapy can be proposed with a curative intent. Some reports have suggested that radiotherapy could have a role in local control of oligometastatic lymph node disease. This is the first reported case of [11C]choline positron emission tomography-guided helical tomotherapy concomitant with estramustine for the treatment of pelvic-recurrent prostate cancer. At 24 months after the end of helical tomotherapy, prostate-specific…

OncologyMaleCancer Researchmedicine.medical_treatment[11C]choline-PET tomotherapy prostate relapse lymph node030218 nuclear medicine & medical imagingCholineProstate cancer0302 clinical medicineProstateCarbon RadioisotopesTomographyLymph nodeAdjuvantPelvic NeoplasmsrelapseprostateGeneral MedicineAlkylatingmedicine.anatomical_structureTreatment OutcomeLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesis[11C]choline-PETEstramustineAged; Antineoplastic Agents Alkylating; Antineoplastic Agents Hormonal; Carbon Radioisotopes; Chemotherapy Adjuvant; Choline; Estramustine; Humans; Male; Neoplasm Recurrence Local; Pelvic Neoplasms; Prostatic Neoplasms; Radiotherapy Adjuvant; Treatment Outcome; Positron-Emission Tomography; Tomography Spiral ComputedEstramustinemedicine.drugmedicine.medical_specialtyAntineoplastic Agents HormonaltomotherapyAntineoplastic AgentsTomotherapy03 medical and health sciencesInternal medicinemedicinelymphChemotherapyHumansAntineoplastic Agents AlkylatingAgedChemotherapyHormonalRadiotherapybusiness.industryProstatic Neoplasmsmedicine.diseaseRadiation therapyNeoplasm RecurrenceConcomitantPositron-Emission TomographySpiral ComputedRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessTomography Spiral Computed
researchProduct

Īslaicīgu dzīves kvalitāšu izmaiņu un komplikāciju salīdzinājums pēc atvērtas un laparoskopiskas prostatektomijas

2020

Ievads: Prostatas vēzis ieņem pirmo vietu vīriešiem starp onkoloģiskām saslimšanām Latvijā radikālu prostatektomiju (RP) skaits pieaug. Lokalizēta prostatas vēža ārstēšanai, tiek pielietotas divu veidu procedūras: atvērta un laparoskopiska RP. Ir nepieciešams izvērtēt, kura procedūra sniegs labākus rezultātus pacientam pēc operācijas un mazāk izmainīs dzīves kvalitāti pēc tās. Darba mērķis: Analizēt, kura operācijas pieeja ir ar mazāk komplikācijām un mazāk ietekmē dzīves kvalitāti pacientam. Materiāli un metodes: Prospektīvs pētījums. Tika pielietota aptaujas pētījuma metode. Pacienti iestājās uz plānveida operāciju, ir divas grupas – atvērta RP un laparoskopiska RP. RLP grupā tika iekļaut…

Laparoskopiska prostatektomijaKomplikācijasRadikāla retropubiska prostatektomijaDzīves kvalitāteMedicīna
researchProduct